Allakos Inc. Stock price

Equities

ALLK

US01671P1003

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
1.23 USD -6.11% Intraday chart for Allakos Inc. -14.58% -54.95%
Sales 2024 * - Sales 2025 * - Capitalization 108M
Net income 2024 * -106M Net income 2025 * -75M EV / Sales 2024 * -
Net cash position 2024 * 82.26M Net cash position 2025 * 193M EV / Sales 2025 * -
P/E ratio 2024 *
-1.03 x
P/E ratio 2025 *
-1.64 x
Employees 131
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.79%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Allakos Inc.

1 day-6.11%
1 week-13.99%
Current month-16.89%
1 month-1.60%
3 months-59.00%
6 months-50.80%
Current year-54.95%
More quotes
1 week
1.20
Extreme 1.2
1.50
1 month
1.20
Extreme 1.2
1.69
Current year
1.00
Extreme 1
3.36
1 year
1.00
Extreme 1
5.64
3 years
1.00
Extreme 1
120.62
5 years
1.00
Extreme 1
157.98
10 years
1.00
Extreme 1
157.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 17-03-31
President 54 17-03-31
Director of Finance/CFO 54 21-04-18
Members of the board TitleAgeSince
Director/Board Member 66 16-03-31
Chairman 58 17-02-28
Chief Executive Officer 54 17-03-31
More insiders
Date Price Change Volume
24-03-18 1.23 -6.11% 697,814
24-03-15 1.31 +0.38% 682,466
24-03-14 1.305 -6.45% 655,961
24-03-13 1.395 +4.89% 597,977
24-03-12 1.33 -7.64% 502,993

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Allakos Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is conducting pre-clinical studies with AK007, which is designed to block known ligand interaction with Siglec-10. It is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.23 USD
Average target price
2.9 USD
Spread / Average Target
+135.77%
Consensus
  1. Stock
  2. Equities
  3. Stock Allakos Inc. - Nasdaq